Solana (NASDAQ:HSDT – Get Free Report) announced its quarterly earnings results on Friday. The company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.03), Zacks reports. Solana had a negative net margin of 1,427.15% and a negative return on equity of 67.57%. The business had revenue of $2.53 million for the quarter, compared to analyst estimates of $3.50 million.
Here are the key takeaways from Solana’s conference call:
- Institutional infrastructure launched: Solana Company’s first validated cluster is operational in Tokyo, with approximately 500,000 SOL in committed third-party stake and validator-related revenue expected to begin in the third quarter.
- Staking performance remained strong: The company generated $2.5 million, or 31,200 SOL, in second-quarter staking revenue and achieved a 6.14% net annualized yield versus a network average of approximately 5.68%.
- Legacy-business transition advanced: The cash-consuming medical-device business was divested, while the company completed its acquisition of a Hong Kong regulated trust company on July 15 for $2 million to support its Asia-Pacific institutional strategy.
- GAAP losses remained substantial: The company reported a $30.3 million second-quarter net loss, including a $25.4 million realized loss on digital assets, while general and administrative expenses rose to $11.1 million, although management expects costs to decline as divestiture-related expenses end.
- Capital allocation will remain valuation-dependent: Solana Company repurchased $2.3 million of shares during the quarter while trading below net asset value, but management said future buybacks, SOL purchases, or business investment will depend on which option offers the greatest SOL-per-share accretion.
Solana Trading Down 5.6%
HSDT stock traded down $0.10 during mid-day trading on Friday, hitting $1.70. 137,150 shares of the company were exchanged, compared to its average volume of 106,755. The firm has a fifty day simple moving average of $1.67 and a 200 day simple moving average of $1.95. The company has a market capitalization of $99.26 million, a PE ratio of -0.02 and a beta of 1.01. Solana has a twelve month low of $1.19 and a twelve month high of $25.50.
Analysts Set New Price Targets
Get Our Latest Analysis on Solana
Hedge Funds Weigh In On Solana
A number of hedge funds have recently bought and sold shares of HSDT. OMERS ADMINISTRATION Corp bought a new stake in Solana during the fourth quarter valued at $88,000. Cetera Investment Advisers bought a new stake in shares of Solana during the 4th quarter valued at about $347,000. XTX Topco Ltd bought a new position in Solana in the fourth quarter worth about $140,000. State Street Corp bought a new position in Solana in the fourth quarter worth about $464,000. Finally, LPL Financial LLC grew its holdings in shares of Solana by 120.1% during the fourth quarter. LPL Financial LLC now owns 382,255 shares of the company’s stock valued at $1,105,000 after purchasing an additional 208,558 shares during the last quarter. 18.63% of the stock is currently owned by institutional investors and hedge funds.
Trending Headlines about Solana
Here are the key news stories impacting Solana this week:
- Positive Sentiment: Management expects to receive its first validator-related rewards in the third quarter of 2026. The company has committed approximately 0.5 million SOL to support its Tokyo validator cluster, potentially creating an additional recurring revenue stream. Solana Company expects first validator-related rewards in Q3 2026
- Positive Sentiment: Second-quarter revenue rose to approximately $2.5 million from $43,000 a year earlier, driven primarily by staking. Solana Company also earned 31,200 SOL in staking rewards, launched its first institutional validator cluster in Tokyo, expanded across Asia-Pacific, and completed the divestiture of its legacy PoNS medical-device business. Solana Company Reports Second Quarter 2026 Financial Results
- Positive Sentiment: The company raised $7.9 million through a registered direct offering and repurchased approximately $2.3 million of shares during the quarter. Partnerships with the Jito Foundation and organizations in Kazakhstan could support future infrastructure and advisory growth.
- Neutral Sentiment: Management’s earnings call emphasized a strategy built around SOL treasury growth, staking yield, validator infrastructure and advisory services, but future rewards and customer pipelines remain dependent on execution and digital-asset market conditions. Solana Company Q2 2026 Earnings Call Transcript
- Negative Sentiment: Profitability remained a major concern. Coverage cited an adjusted quarterly loss of $0.05 per share versus an expected loss of $0.02, while revenue of $2.53 million missed the $3.50 million consensus estimate. The company’s reported net loss was $30.3 million, with operating expenses of $35.1 million and general and administrative costs of $11.1 million. Solana Company Reports Q2 Loss, Lags Revenue Estimates
- Negative Sentiment: Wall Street Zen downgraded HSDT to “Sell,” adding to bearish sentiment. The company also held only $3.6 million in cash at quarter-end and reported a cumulative deficit of $342.6 million, underscoring financing and execution risks. Wall Street Zen Downgrades Solana to Sell
Solana Company Profile
Helius Medical Technologies, Inc (NASDAQ: HSDT) is a medical technology company focused on developing and commercializing non‐invasive neuromodulation platforms designed to enhance neurorehabilitation. Its flagship product, the Portable Neuromodulation Stimulator (PoNS®), delivers mild electrical pulses to the tongue to stimulate neural pathways in conjunction with targeted physical therapy. The device is intended to improve neuroplasticity and support recovery in patients with neurological conditions.
The PoNS system is cleared for use in the United States, Canada and the European Union and is prescribed through specialized rehabilitation clinics.
Read More
- Five stocks we like better than Solana
- Is Best Buy the AI Winner Hiding in the Electronics Aisle?
- Applied Materials Beat Everything but Wall Street’s Expectations for Margins
- Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
- Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing
Receive News & Ratings for Solana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solana and related companies with MarketBeat.com's FREE daily email newsletter.
